EU/3/22/2720: Orphan designation for the treatment of adrenoleukodystrophy

(R)-deuteropioglitazone hydrochloride

Table of contents

Overview

This medicine was designated as an orphan medicine for the treatment of adrenoleukodystrophy in the European Union on 11 November 2022.

This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.

Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:

Key facts

Active substance
(R)-deuteropioglitazone hydrochloride
Intended use
Treatment of adrenoleukodystrophy
Orphan designation status
Positive
EU designation number
EU/3/22/2720
Date of designation
11/11/2022
Sponsor

Poxel
259 Avenue Jean Jaures
Immeuble Le Sunway
69007 Lyon
France
E-mail: contact@poxelpharma.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating